{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-053088","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.700021+00:00","generated_at":"2026-06-08T03:16:53.705561+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Femasys Q3 net loss widens to $4.0M, revenue down 30%; FemaSeed gets FDA clearance","bullets":["Net loss of $4.0M ($0.26/share) vs $3.0M ($0.25) in Q3 2022.","Revenue $244K, down 30% from $347K; U.S. units down 18.4% YoY.","Raised $11.3M via warrant exercises and ATM; cash $8.7M sufficient for >12 months.","FDA 510(k) clearance for FemaSeed infertility treatment; FINALE trial for FemBloc enrolling.","Gross margin improved to 64.7% from 62.2% on manufacturing efficiencies."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-053088","json":"https://secwatch.observer/filing/0001140361-23-053088.json","markdown":"https://secwatch.observer/filing/0001140361-23-053088.md","text":"https://secwatch.observer/filing/0001140361-23-053088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123053088/0001140361-23-053088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123053088/ef2001466_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:16:53.705561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3ba520e8731c6c217b8f090dac21ac217f7ffa0","claim":"FEMASYS INC reported the third quarter ended September 30, 2023 results: revenue $244,361.","evidence_excerpt":"2022. The increase was largely due to increased compensation and professional costs, partially offset by decreased facility and overhead costs. • Sales decreased by $103,095 to $244,361 for the three months ended September 30, 2023 compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123053088/0001140361-23-053088-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$244,361"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}